Telix Pharmaceuticals (TLPPF)
Canaccord Genuity analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals on August 20 and set a price target of A$28.25. The company’s shares closed last Friday at $10.20, close to its 52-week low of $8.14.
Storey has an average return of 41.8% when recommending Telix Pharmaceuticals.
According to TipRanks.com, Storey is ranked #5019 out of 12498 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Telix Pharmaceuticals with a $18.05 average price target, which is a 77.0% upside from current levels. In a report issued on August 20, TipRanks – PerPlexity also upgraded the stock to Buy with a A$18.50 price target.
